Clinical Trial Detail

NCT ID NCT02689427
Title Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Enzalutamide + Paclitaxel

Age Groups: adult

No variant requirements are available.